Balancing the efficacy and safety of vaccines in the elderly

Open Longevity Science

Volumn 6, Issue , 2012, Pages 64-72

  Amanna, Ian J ^a  

^a Najit Technologies Inc   (United States)

Author keywords

Ageing; Immunity; Immunosenescence; Vaccines

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; RABIES VACCINE; TYPHOID VACCINE; VARICELLA ZOSTER VACCINE; YELLOW FEVER VACCINE;

AGE DISTRIBUTION; CELLULAR IMMUNITY; COMMUNITY ACQUIRED PNEUMONIA; DOSE RESPONSE; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELDERLY CARE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE PRACTICE; HEPATITIS A; HERPES ZOSTER; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JAPANESE ENCEPHALITIS; LETHARGY; LIFE EXPECTANCY; LOW DRUG DOSE; MALAISE; MASS IMMUNIZATION; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; NOSE IRRITATION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RABIES; REVIEW; RHINORRHEA; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEASONAL INFLUENZA; SENESCENCE; SORE THROAT; STREPTOCOCCUS PNEUMONIA; THROAT IRRITATION; TYPHOID FEVER; VACCINE FAILURE; VISCEROTROPIC DISEASE; YELLOW FEVER;

EID: 84863973466     PISSN: None     EISSN: 1876326X     Source Type: Journal    
DOI: 10.2174/1876326X01206010064     Document Type: Review

References (95)

1. U.N. World Population Prospects: The 2008 Revision, Highlights. 2008. New York: Dept. of Economic and Social Affairs PD 2009.
2. Lutz W, Sanderson W, Scherbov S. Doubling of world population unlikely. Nature 1997; 19387(6635): 803-805.
3. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002; 2(11): 659-666.
4. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: Final Data for 2007. Natl Vital Stat Rep 2010; 58(19): 1-135.
5. Mortality Rates 1910-1920. Washington: Bureau of the Census, Government Printing Office 1923.
6. th ed. Philadelphia, PA: Saunders/Elsevier 2008; pp. 353-98.
7. Panum PL, Petersen JJ. Observations made during the epidemic of measles on the Faroe Islands in the year 1846. New York: Delta Omega Society; distributed by the American Public Health Association; 1940.
8. th ed. New York: Plenum Medical Book Co 1997; pp. 507-529.
9. Christensen PE, Schmidt H, Bang HO, Andersen V, Jordal B, Jensen O. An epidemic of measles in southern Greenland, 1951; measles in virgin soil. II. The epidemic proper. Acta Med Scand 1953; 144(6): 430-449.
10. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9(9): 1131-1137.
11. Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003; 289(24): 3295-3299.
12. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003 Nov 15; 171(10): 4969-4973.
13. Taub DD, Ershler WB, Janowski M, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008; 121(12): 1058-1064.
14. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. The History of Smallpox and its Spread Around the World. Smallpox and its eradication. Geneva: World Health Organization 1988; p. 1469.
15. Hill DR. Pre-travel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service. Am J Trop Med Hyg 1991; 45(2): 263-270.
16. Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009; 30(7): 351-359.
17. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing 2007; 4: 9.
18. High K. Immunizations in older adults. Clin Geriatr Med 2007; 23(3): 669-85, viii-ix.
19. CDC. Recommended Adult Immunization Schedule - United States, 2011. MMWR Morb Mortal Wkly Rep 2011; 4: 60(4).
20. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20(13-14): 1831-1836.
21. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005; 165(3): 265-272.
22. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, Hall AJ. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004; 190(1): 1-10.
23. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside flu season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178(5): 527-533.
24. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35(2): 337-344.
25. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24(8): 1159-1169.
26. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53(RR-6): 1-40.
27. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272(21): 1661-1665.
28. Meldrum ML. The historical feud over polio vaccine: how could a killed vaccine contain a natural disease? West J Med 1999; 171(4): 271-3.
29. MedImmune. FluMist Package Insert. Gaithersburg: MedImmune June 16 2010; p. 10.
30. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338(20): 1405-1412.
31. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25(10): 860-869.
32. Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses. 2011; 5(2): 67-75.
33. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361(13): 1260-1267.
34. De Villiers PJ, Steele AD, Hiemstra LA, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009; 28(1): 228-234.
35. Praditsuwan R, Assantachai P, Wasi C, Puthavatana P, Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai 2005; 88(2): 256-264.
36. Edwards KM, Dupont WD, Westrich MK, Plummer WD, Jr., Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169(1): 68-76.
37. Treanor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117(8): 625-633.
38. Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Rev Vaccines 2009; 8(4): 483-492.
39. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19(17-19): 2673-2680.
40. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49(3): 177-184.
41. Iannazzo S. Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. J Prev Med Hyg 2011; 52(1): 1-8.
42. CDC. Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59(16): 485-486.
43. Sullivan SJ, Jacobson R, Poland GA. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine. Expert Rev Vaccines 2010; 9(10): 1127-1133.
44. Sanofi-Pasteur. Fluzone Package Insert. July 14 ed. Swiftwater: Sanofi-Pasteur; 2010. p. 6.
45. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200(2): 172-180.
46. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166(10): 1121-1127.
47. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25(44): 7656-7663.
48. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47(10): 1328-1338.
49. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46(7): 1015-1023.
50. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180(1): 48-58.
51. Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ 2010; 340: c1004.
52. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007; 25(20): 4029-4037.
53. Scott D, Ruckle J, Dar M, Baker S, Kondoh H, Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 2008; 50(3): 295-299.
54. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007; 25(33): 6164-6166.
55. Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66(9): 378-383.
56. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27(2): 159-176.
57. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27(9): 1454-1467.
58. Schmader K, Gnann JW, Jr., Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008; 197 (Suppl. 2): S207-S215.
59. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22): 2271-2284.
60. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200(7): 1068-1077.
61. Merck. Zostavax Package Insert. Whitehouse Station: Merck December 2009; p. 7.
62. Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis 2008; 197 (Suppl. 2): S237-S241.
63. Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989; 320(14): 892-897.
64. Sperber SJ, Smith BV, Hayden FG. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral Res 1992; 17(3): 213-222.
65. Levine MJ, Ellison MC, Zerbe GO, et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18(25): 2915-2920.
66. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347(1): 26-34.
67. Leder K, Weller PF, Wilson ME. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 2001; 33(9): 1553-1566.
68. Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994; 272(11): 885-889.
69. Genton B, D'Acremont V, Furrer HJ, Hatz C, Louis L. Hepatitis A vaccines and the elderly. Travel Med Infect Dis 2006; 4(6): 303-312.
70. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987; 317(18): 1101-1104.
71. Berna-Biotech. Vivotif® Package Insert. Coral Gables: Berna Biotech August 2006; p. 3.
72. CDC. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42(RR-1): 1-15.
73. Kanamitsu M, Hashimoto N, Urasawa S, Katsurada M, Kimura H. A field trial with an improved Japanese encephalitis vaccine in a nonendemic area of the disease. Biken J 1970; 13(4): 313-328.
74. Ceddia T, Natellis C, Zigrino AG. Antibody response to rabies vaccine prepared in tissue cultures of human diploid cells and inactivated, evaluated in different classes of age. Ann Sclavo. 1982; 24(5): 491-495.
75. Mastroeni I, Vescia N, Pompa MG, Cattaruzza MS, Marini GP, Fara GM Immune response of the elderly to rabies vaccines. Vaccine 1994; 12(6): 518-520.
76. Fishbein DB, Yenne KM, Dreesen DW, Teplis CF, Mehta N, Briggs DJ. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine 1993; 11(14): 1390-1394.
77. Russell MN, Cetron MS, Eidex RB. The US-Certified Yellow Fever Vaccination Center Registry: a tool for travelers, state health departments, and vaccine providers. J Travel Med 2006; 13(1): 48-49.
78. Tomori O. Yellow fever: the recurring plague. Crit Rev Clin Lab Sci 2004; 41(4): 391-427.
79. th ed. Philadelphia, PA: Saunders/Elsevier 2008; pp. 959-1056.
80. Khromava AY, Eidex RB, Weld LH, et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005; 23(25): 3256-3263.
81. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26(48): 6077-6082.
82. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004; 22(17-18): 2103-2105.
83. Pugachev KV, Guirakhoo F, Monath TP. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005; 18(5): 387-394.
84. Hindle E. A Yellow Fever Vaccine. Br Med J 1928; 1: 976-977.
85. Pettit A. Rapport sur la valeur immunisante des vaccins employés contre le fièvre jaune et la valeur thérapeutique du sérum antiamaril. Bull Acad Méd 1931; 105: 522-526.
86. Gaspar LP, Mendes YS, Yamamura AM, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008; 150(1-2): 57-62.
87. Monath TP, Lee CK, Julander JG, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010; 28(22): 3827-3840.
88. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43(7): 860-868.
89. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348(18): 1747-1755.
90. Fernandes R, Valcour V, Flynn B, Masaki K, Blanchette P. Tetanus immunity in long-term care facilities. J Am Geriatr Soc 2003; 51(8): 1116-1119.
91. Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005; 23(25): 3232-3235.
92. Alagappan K, Rennie W, Kwiatkowski T, Narang V. Antibody protection to diphtheria in geriatric patients: need for ED compliance with immunization guidelines. Ann Emerg Med 1997; 30(4): 455-458.
93. Hutchins WA, Carlone GM, Westerink MA. Elderly immune response to a TI-2 antigen: heavy and light chain use and bactericidal activity to Neisseria meningitidis serogroup C polysaccharide. J Infect Dis 1999; 179(6): 1433-1440.
94. Oyeyinka GO, Salimonu LS, Balogun B, Idowu JR. Responses to tuberculin and meningococcal polysaccharide vaccination during ageing in Nigerians. Ann Trop Med Parasitol 1995; 89(3): 317-320.
95. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002; 35(11): 1368-1375.